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Introduction
One of the key criteria in the process of approving a new drug is 
clinical relevance of the results. Randomized controlled trials 
(RCTs) are usually limited to several months in length, and sam-
ple sizes have been calculated based on surrogate endpoints like 
drinking behavior, such as abstinence periods or reduction of 
drinking (European Medicines Agency, 2010; Food and Drug 
Administration, 2015). Clinical benefits or clinical relevance in 
terms of reduction of morbidity or mortality have to be estab-
lished indirectly in most cases as the underlying trials are time-
limited (e.g. efficacy trials and safety trials up to 12–15 months; 
see European Medicines Agency, 2010; Food and Drug 
Administration, 2015). For abstinence, it has been demonstrated 
that stable abstinence over such time predicts long term absti-
nence (Dawson et al., 2007; Weisner et al., 2003) and various 
clinical relevant endpoints such as functionality, co-morbidity, or 
mortality (Kaskutas et al., 2014; Roerecke et al., 2013).
For reduction of drinking, which can be used for evaluating 
efficacy of treatment with respect to clinical relevance, it seems 
harder to find a standard. The treatment goal of reduction in 
drinking is less well established and informed by a lower level of 
evidence and consensus. For the US, the Food and Drug 
Administration has proposed the standard of no heavy drinking 
days (Delucchi and Weisner, 2010; Food and Drug Administration, 
2015; Sanchez-Craig et al., 1995). In Europe, the EMA (European 
Medicines Agency, 2010) has created categories of drinking lev-
els associated with different risks for relevant clinical outcomes, 
mainly based on chronic disease and injury (World Health 
Organization, 2000). A recent publication applied principles 
outlined in the EMA guideline for evaluation of clinical relevance 
of reduction of alcohol consumption in clinical trials to biomark-
ers and quality of life measures (Aubin et al., 2015). Of special 
importance seems mortality as the most severe endpoint associ-
ated with alcohol use disorders in general and alcohol depend-
ence in particular (Harris and Barraclough, 1998; Roerecke and 
Rehm, 2013, 2014). The work of Laramée et al. can be consid-
ered as examples (François et al., 2014; Laramée et al., 2014) to 
demonstrate how the differences found in clinical trials (Van den 
Brink et al., 2013, 2014) would lead to clinically relevant out-
comes, if they persisted, or if the effects were found in larger 
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samples (see also Barbosa et al., 2010 for a modeling of different 
outcomes, such as quality-adjusted life years and costs).
All the studies cited above share one assumption: that the risk 
curves for various disease or cause of death categories (for an 
overview, please see Rehm et al., 2010; Shield et al., 2013) can 
actually be applied to changes in consumption by individuals 
over time. Thus, if 100 g pure alcohol/day is associated with a 
certain risk for liver disease incidence or liver disease mortality, 
and 30 g with a lower risk based on epidemiological studies 
(Rehm et al., 2010), then it is assumed that if an individual 
switches from 100 g to 30 g pure alcohol per day, this individual 
would reduce his or her risk accordingly. While this assumption 
is plausible, there are not enough studies to show that real reduc-
tions by individuals were associated with risk reductions. 
However, there are enough studies with all-cause mortality. 
Meta-analyses of these studies have shown that a reduction in 
drinking (odds ratio [OR] = 0.41, 95% CI: 0.34, 0.50), regardless 
of achieving actual abstinence, was associated with a reduction in 
average mortality risk after treatment for alcohol dependence, 
although abstinence showed the strongest association with 
reduced mortality (Roerecke et al., 2013). We used an indirect 
approach to estimate the most important indicator for clinical rel-
evance (namely mortality risk) for nalmefene treatment in com-
parison to a placebo. We are assuming that the reduced drinking 
levels in the RCTs is maintained on average 3.5 years, which is 
the average assessment of drinking levels after baseline in the 
meta-analyses by Roerecke et al. (2013). Because both reduced 
drinking and abstinence have been associated with a reduced 
mortality risk in comparison to continued heavy drinking, two 
scenarios (Scenario I and II) were used to estimate mortality risk.
Methods and materials
In this report we used participants with a high or very high drink-
ing risk level (DRL, as defined by WHO; European Medicines 
Agency, 2010) at both the screening visit (covering drinking in 
the prior 4 weeks) and the randomization visit, which corre-
sponds to the population indicated for the use of nalmefene 
(resulting in n = 641 from 6-months RCTs and n = 183 from the 
1-year RCT with at least one valid post-randomization assess-
ment of drinking). In addition to abstinence, the following DRLs 
were used for patient assessment throughout the RCTs: 1–20 g 
pure alcohol per day, >20–40 g, >40–60 g, >60 g (women); 1–40 
g, >40–60 g, >60–100 g, >100 g (men) for low, medium, high, 
and very high risk, respectively (from European Medicines 
Agency, 2010). Abstinence or low DRL were defined as a reduced 
drinking at the end of each trial. Missing values were handled 
using the last observation carried forward for the main analyses 
(Scenarios I and II). In sensitivity analyses, a mixed model 
repeated measures (MMRM) was used. Data from the RCTs are 
displayed in Tables 1 and 2.
Data sources
We used data from two sources for this analysis.
The first source was data from two double-blind RCTs 
(NCT00811720; NCT00812461) investigating drinking levels up to 
6 months (Gual et al., 2013; Mann et al., 2013; Van den Brink et al., 
2013) and one double-blind RCT (NCT00811941) investigating 
drinking levels up to 1 year (Van den Brink et al., 2014) comparing 
nalmefene versus placebo (both in combination with psychosocial 
support). All RCTs received ethics approval and all patients gave 
informed written consent.
Briefly, the two 6-months RCTs were conducted in Germany, 
Finland, Sweden, and Austria (Mann et al., 2013), and in 
Belgium, Czech Republic, France, Italy, Poland, Portugal, and 
Spain (Gual et al., 2013) from December 2008 to July 2010. The 
1-year RCT was conducted between March 2009 and September 
2010 in the Czech Republic, Estonia, Hungary, Latvia, Lithuania, 
Poland, Russia, Slovakia, Ukraine, and the UK (Van den Brink 
et al., 2014). Main eligibility criteria were (Gual et al., 2013; 
Mann et al., 2013; Van den Brink et al., 2014): ⩾18 years of age, 
primary diagnosis of alcohol dependence (American Psychiatric 
Association, 2000) assessed by the Mini-International 
Neuropsychiatric Interview (Lecrubier et al., 1997), and blood 
alcohol level <0.02% at screening.
Main exclusion criteria were (Gual et al., 2013; Mann et al., 
2013; Van den Brink et al., 2014): <6 heavy drinking days (⩾60 
g/day for men and ⩾40 g/day for women; European Medicines 
Agency, 2010) in the 4 weeks before screening, average alcohol 
consumption below medium risk levels (for the two 6-month tri-
als, the 12-month one including low risk levels), >14 consecutive 
abstinent days in the 4 weeks before screening, a score ⩾10 (indi-
cating the need for medication-supported detoxification) on the 
Table 1. Drinking risk level at baseline and month 6 from two 6-month 
double-blind randomized controlled trials.
Time point Women (n = 217) Men (n = 424)
Drinking risk level Placebo Nalmefene Placebo Nalmefene
Baseline
 High 25 29 109 91
 Very high 86 77 102 122
Month 6
 Abstinence or low 30 33 71 96
 Medium or above 81 73 140 117
Note: Drinking risk level (DRL, low, medium, high, very high) as defined in the 
Methods section. Missing values were handled using the last observation carried 
forward.
Table 2. Drinking risk level at baseline and month 13 from the 1-year 
double-blind randomized controlled trials.
Time point Women (n = 42) Men (n = 141)
Drinking level Placebo Nalmefene Placebo Nalmefene
Baseline
 High 4 10 19 63
 Very high 6 22 13 46
Month 13a
 Abstinence or low 3 19 13 63
 Medium or above 7 13 19 46
a13 months of 28 days.
Note: Drinking risk level (DRL, low, medium, high, very high) as defined in the 
Methods section. Missing values were handled using the last observation carried 
forward.
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revised version of the Clinical Institute Withdrawal Assessment 
for Alcohol (CIWA-Ar; Sullivan et al., 1989), aspartate ami-
notransferase or alanine aminotransferase values >3 times of 
upper normal limit, current DSM-IV Axis 1 disorder other than 
alcohol dependence, DSM-IV Axis II antisocial personality disor-
der, or recent (within 1 week prior to the screening) treatment with 
opioid agonists or partial agonists. In the 1-year RCT, patients 
with stable comorbid psychiatric disorders were eligible (Van den 
Brink et al., 2014). For a more detailed description of selection 
criteria, please see supplementary appendices in Mann et al. 
(2013), Van den Brink et al. (2014), and Gual et al. (2013).
One nalmefene tablet (18 mg) was to be taken on each day 
when risk of drinking was perceived, preferably 1–2 hours before 
the anticipated time of drinking. Drinking (daily number of stand-
ard drinks) and medication intake throughout the trials were 
recorded with Timeline Follow-back (Sobell and Sobell, 1992). 
Country-specific conversion factors were used to transform drink-
ing into g/day, and patients were provided with a conversion card. 
In addition to nalmefene or placebo, all participants participated 
in a motivational and adherence-enhancing intervention 
(BRENDA, (Starosta et al., 2006; Volpicelli et al., 2001)) starting 
at randomization and at each subsequent site visit. No treatment 
goal was specified, i.e. abstinence and a reduction in drinking 
were accepted. Pre-defined primary outcome measures were 
change from baseline in total alcohol consumption and number of 
heavy drinking days. A total of 1711 patients were screened, and 
1322 patients were randomized to as-needed nalmefene or pla-
cebo in the two 6-month RCTs, and 841 patients screened and 675 
patients randomized in the 1-year RCT. The majority of these 
patients had not undergone previous treatment for alcohol depend-
ence or withdrawal symptoms (Van den Brink et al., 2013, 2014).
Secondly, we used data from comprehensive published meta-
analyses (Roerecke et al., 2013) as an indicator for mortality risk, 
and applied the pooled all-cause mortality risk reductions from 
these meta-analyses to the reductions in alcohol consumption 
observed in the above mentioned RCTs. In total, data from 16 
primary studies were included in these meta-analyses, contribut-
ing to 755 observed deaths, with 4951 people at risk (Roerecke 
et al., 2013). The time from baseline to follow-up of drinking 
status (abstinence, reduced drinking, or relapse/continued heavy 
drinking) ranged from 1 to 15 years with a weighted mean of 3.5 
years, and the time from baseline to mortality or end of study 
ranged from 3 to 16 years with a weighted mean of 8.8 years.
In Scenario I, we used pooled mortality risks based on reduced 
drinking including abstinence versus continued heavy drinking, 
and in Scenario II we used pooled mortality risks based on 
reduced drinking excluding abstinence versus continued heavy 
drinking. In other words: Scenario I used an OR of 0.41 (95% CI: 
0.34, 0.50), based on reduced drinking including abstinence ver-
sus continued heavy drinking (Roerecke et al., 2013), and 
Scenario II, a more conservative analysis (considering that some 
patients became abstinent with nalmefene treatment during 
RCTs), used an OR of 0.61 (95% CI: 0.39, 0.94), based on 
reduced drinking excluding abstinence versus continued heavy 
drinking (Roerecke et al., 2013).
Derivation of mortality risk estimates
The data from the RCTs presented in Table 1 and 2 were com-
bined with reported mortality risk estimates by drinking level 
after alcohol treatment from the meta-analyses of Roerecke et al. 
(2013) using the following formula for relative risk (RR) of mor-
tality of nalmefene versus placebo:
Relative Risk of mortality  
nalmefene versus placebo
,
=
∑ i nap ,
,
i i
i
pl i i
OR
p OR∑
where pna,i is the prevalence of DRLi in the nalmefene group, ppl,i 
is the prevalence of DRLi in the placebo group, and ORi is the OR 
for DRLi, which was the same for the nalmefene and placebo 
groups. With respect to confidence intervals, for each analysis, 
100,000 Monte Carlo simulations were computed based on the 
following approach:
a) Two sources of uncertainty were entered: the prevalence 
of the respective category, and the OR,
b) The uncertainty of prevalence was derived from the SE 
as p p
n
( )1− ,
c) The uncertainty of the OR was based on the meta-analy-
ses from Roerecke et al. (2013).
As customary in analyses of OR, it was assumed that the distribu-
tion of the logarithmic risk was normally distributed (Fleiss et al., 
2003; Rothman et al., 2008). The relative risks of mortality, 
nalmefene versus placebo, were pooled across trials using 
inverse-variance weighted DerSimonian–Laird random-effect 
models to allow for potential between-study heterogeneity 
(DerSimonian and Laird, 1986). Sensitivity analyses were per-
formed varying the prevalence estimates from the RCTs with 
missing values imputed using individual patient-predicted values 
of total alcohol consumption (g pure alcohol/day) derived from a 
MMRM used in the primary analysis of total alcohol consump-
tion in the nalmefene RCTs (Gual et al., 2013; Mann et al., 2013; 
Van den Brink et al., 2014). Between-study heterogeneity was 
quantified using the I2 statistic (Higgins and Thompson, 2002). 
All meta-analytical analyses were performed on the natural log 
scale in Stata statistical software, version 12 (Stata Corp, College 
Station, Texas).
Results
Scenario I
Assuming an OR of 0.41 (95% CI: 0.34, 0.50) for reduced drink-
ing including abstinence, the 9-year estimated mortality risks in 
the nalmefene group versus the placebo group after combining 
the data from the nalmefene RCTs with the data from the meta-
analysis are presented in Figure 1. The overall treatment effect of 
nalmefene versus placebo was predicted to reduce the estimated 
9-year mortality risk on average by 8% (95% CI: 2%, 13%).
Scenario II
Assuming an OR of 0.61 (95% CI: 0.39, 0.94) for reduced drink-
ing (based on studies with data on reduced drinking, excluding 
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s t u d i e s  w i t h  o n l y  a b s t i n e n c e  d a t a ;  s e e  R o e r e c k e  e t  al., 2013), the 
mortality risks in the nalmefene group versus the placebo group 
after combining the data from the nalmefene RCTs with the data 
from the meta-analysis are presented in Figure 2. The overall 
treatment effect of nalmefene versus placebo was predicted to 
reduce the estimated 9-year mortality risk on average by 4% 
(95% CI: 0%, 8%).
Sensitivity analyses
Sensitivity analyses were performed using the DRLs with miss-
ing values imputed using individual patient-predicted values of 
total alcohol consumption as described above. For Scenario I, the 
overall treatment effect of nalmefene versus placebo was pre-
dicted to reduce the estimated 9-year mortality risk on average by 
9% (RR: 0.91; 95% CI: 0.86, 0.96); and for the Scenario II, the 
overall treatment effect was 5% (RR: 0.95; 95% CI: 0.91, 0.99). 
Thus, the predicted mortality reductions were slightly higher 
when using MMRM imputation for missing values than using a 
last observation carried forward imputation for handling missing 
values in the nalmefene RCTs.
Discussion
Before discussing the results and implications of the study, we 
would like to point out potential limitations.
Limitations
Data included in the original meta-analysis on reduced drinking 
were derived from 16 published studies with various definitions 
of reduced drinking, including abstinence. The low DRL can be 
seen as a conservative interpretation of reduced drinking; many 
of the studies included in the original meta-analyses by Roerecke 
et al. (2013) had more lenient definitions and higher thresholds as 
reduced drinking after alcohol treatment. Thus, it is justified to 
use low DRL to define reduced drinking. However, while the 
definition of reduced drinking is conservative with medium DRL 
considered as no improvement in heavy drinking, the proportion 
of abstainers in the studies included in the meta-analyses of 
Roerecke et al. (2013) was higher than that in the nalmefene 
RCTs. Therefore, Scenario II was performed using the OR for 
reduced drinking excluding abstinence (based on studies with 
data on reduced drinking, excluding studies with only abstinence 
data; see Roerecke et al., 2013). This estimate is conservative, as 
there were abstinence outcomes observed in the nalmefene RCTs. 
Furthermore, we are assuming that any reduction in drinking dur-
ing the RCTs is maintained after the conclusion of the trials. The 
mean assessment of drinking status after treatment was 3.5 years 
in the meta-analyses used to estimate mortality risks associated 
with a reduction in drinking levels, and mortality was ascertained 
after a mean of 8.8 years after baseline. The second assumption is 
that the RCTs and studies included in the meta-analyses have 
comparable populations. While all participants in both RCTs and 
Overall
Women (pooled 6-month)
Men (1-year study)
Men (pooled 6-month)
Women (1-year study)
Subtotal
Subtotal
12 months
Studies
6 months
0.92 (0.87, 0.98)
0.97 (0.89, 1.06)
0.87 (0.74, 1.02)
0.92 (0.85, 0.99)
0.79 (0.60, 1.04)
0.85 (0.74, 0.97)
0.94 (0.89, 0.99)
RR (95% CI)
100.00
35.89
11.17
48.95
3.99
15.16
84.84
Weight
%
1.75 1.25
Figure 1. Mortality risks (nalmefene versus placebo) assuming an OR = 0.41 for reduced drinking (including abstinence).
Note: I2 = 6%, p = 0.37 for overall analysis, random-effects model.
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the meta-analyses received treatment for alcohol use disorders, 
many of the studies in the meta-analyses were from an in-patient 
treatment setting and thus may comprise of more severe cases of 
alcohol use disorders. However, no other systematic examina-
tions have been published and thus we used the best data availa-
ble for our study.
Implications
While clinical studies with usual 6 months duration cannot show 
clinical relevance on major outcomes such as mortality, combin-
ing trial data on reduction in drinking levels and mortality risks 
associated with such reductions allowed the estimation of clinical 
relevance. In short, we could show that the reduction of drinking 
following treatment with nalmefene versus placebo had clinical 
relevance with respect to mortality, when combined with results 
from meta-analyses of all relevant clinical studies. In other 
words: the relative drinking level reductions observed in patients 
with a high or very high DRL at screening and randomization 
between compared arms from the nalmefene RCTs (Gual et al., 
2013; Mann et al., 2013; Van den Brink et al., 2013, 2014) are 
large enough to expect reduced mortality in the future. The ques-
tion is, how the effect size of the present study compares to other 
effect sizes. First, the effect sizes of pharmacological treatment 
for alcohol use disorders in general compare favorable to the 
effects of other treatments such as psychotherapy (Miller et al., 
2003; Rehm et al., 2013). The only intervention with higher mor-
tality gains would be brief interventions in certain hospital set-
tings, i.e. for people with high risk of mortality (McQueen et al., 
2011; Rehm and Roerecke, 2013). Second, the absolute gain for 
society would be huge in regions like Europe, where more than 
3% of the adult population fulfill the criteria of alcohol depend-
ence (Rehm et al., 2015a), and most of them would fulfill the 
criteria of high or very high DRL (Rehm et al., 2015b). Finally, 
the effect size against placebo of the underlying studies was simi-
lar to effect sizes for other treatments, e.g. for depression treat-
ment (effect size: numbers needed to treat; Arroll et al., 2009).
While the expected reductions of mortality are relatively 
small, any statistically significant reduction of mortality is 
important, especially given the high mortality risk associated 
with patients in alcohol treatment (Roerecke and Rehm, 2013). 
The results also indicate that reduction of drinking can be clini-
cally relevant on the long term, even if drinking levels are not 
reduced to abstinence. This result is important, since many peo-
ple with alcohol use disorders either are unable or do not want to 
choose abstinence as a treatment goal and some of them will not 
attend treatment for that reason (e.g., Heather et al., 2010; 
Hodgins et al., 1997). On the other hand, treatment goal and 
results may change during treatment or post-treatment, and 
reduction of drinking was not necessarily associated with less 
long-term success (see also Ambrogne, 2002; Sanchez-Craig and 
Lei, 1986; Sanchez-Craig et al., 1984). The proportion of people 
Overall
Subtotal
Subtotal
Women (pooled 6-month)
Men (1-year study)
6 months
Women (1-year study)
Studies
Men (pooled 6-month)
12 months
0.96 (0.92, 1.00)
0.97 (0.93, 1.01)
0.91 (0.82, 1.00)
0.98 (0.93, 1.04)
0.92 (0.82, 1.04)
0.87 (0.72, 1.06)
RR (95% CI)
0.95 (0.89, 1.01)
100.00
85.26
14.74
45.53
10.78
3.96
%
Weight
39.73
1.75 1.25
Figure 2. Mortality risks (nalmefene versus placebo) assuming an OR = 0.61 for reduced drinking (excluding abstinence).
Note: I2 = 0%, p = 0.54 for overall analysis, random-effects model.
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with alcohol use disorders receiving treatment overall is low 
(Alonso et al., 2004, Manthey et al., in press; Rehm et al., 2012), 
and important public health improvements could be made, if 
more people sought treatment (Rehm et al., 2013). The presented 
results clearly support this line of reasoning (see also Nutt and 
Rehm, 2014), and it is hoped that the introduction of pharmaco-
logical agents such as nalmefene will lead to higher treatment 
rates and better survival of people with alcohol dependence.
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